IONS insider Geary exercises options, sells 57,900 shares under 10b5-1 plan
Rhea-AI Filing Summary
Richard S. Geary, EVP & Chief Development Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sales on 09/30/2025. He exercised a non-qualified stock option with a $53.77 exercise price to acquire 57,900 shares, increasing his direct beneficial ownership to 137,557 shares. On the same date he sold 57,900 shares under a Rule 10b5-1 trading plan adopted May 6, 2025, for a weighted-average price of $65.2447 per share, with individual sale prices in the $65.00 to $65.52 range. The filing was submitted by an attorney-in-fact.
Positive
- Exercise and sale were disclosed in a timely Form 4 showing compliance with reporting rules
- Sales executed under a Rule 10b5-1 plan, indicating pre-cleared, pre-arranged transactions
Negative
- Reduction in direct holdings by 57,900 shares due to the reported sale
- Weighted-average sale price reported rather than per-trade prices (detailed per-trade breakdown available on request)
Insights
TL;DR: Insider exercised options and sold the same number of shares under a Rule 10b5-1 plan, netting a realized gain by price difference.
The report shows a routine, same-day option exercise paired with coordinated sales under a pre-established Rule 10b5-1 plan. The exercise at $53.77 and sales at a weighted-average of $65.2447 indicate the reporting person realized a positive spread per share. This is a standard liquidity action often used by executives to monetize vested equity while remaining compliant with insider trading rules. No new grants, unusual derivative structures, or change in control signals are present in this filing.
TL;DR: Transaction appears procedural and compliant; documentation references a formal 10b5-1 plan and attorney-in-fact signature.
The filing explicitly notes the use of a Rule 10b5-1 trading plan adopted May 6, 2025, and contains an attorney-in-fact signature, which supports prearranged and documented execution. The transactions are clearly disclosed with exercise price, sale price range, and resulting beneficial ownership. From a governance perspective, disclosure is complete for the transactions shown and there are no indications of policy breaches or undisclosed related-party arrangements within this Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 57,900 | $0.00 | -- |
| Exercise | Common Stock | 57,900 | $53.77 | $3.11M |
| Sale | Common Stock | 57,900 | $65.2447 | $3.78M |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.52 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
